Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Manhattan Scientifics, Inc. (MHTX)

Add MHTX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 12/12/2017 10:00:16 AM - Followers: 73 - Board type: Free - Posts Today: 0

Our company

The Company's business model capitalizes on inventions and technology from which profits are created through licensing. MSI is dedicated to earning profit for its 8,600 shareholders by identifying, supporting, patenting and marketing technical innovation by harvesting top technology talent to bring game-changing product to the market. We emphasize novel technology in the Nanomedicine space with the potential to be disruptive and the ability to establish sustainable businesses.

We are "patient capital" with experienced business building partners who bring the perspective of merchant bankers, not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune/1000 or larger). The entrepreneurial scientists and engineers who join us create personal success and wealth on an accelerated basis by virtue of ownership of publicly traded Manhattan Scientifics shares (OTC BB: MHTX).


Technology : Advenced Materials


Manhattan Scientifics has acquired the exclusive rights to the key patents and IP and will soon be positioned to enter into manufacturing and licensing agreements.

Nano Titanium

Manhattan Scientific's nanostructured metal technology is based on over 16 years of highly focused research and development. Nanostructured metals and alloys possess significantly enhanced mechanical properties that include, for example, increased strength without concurrent losses in ductility, and significantly increased resistance to fatigue fracture. Nanostructured commercially pure grades of titanium have proven to also possess excellent machinability as well as high toughness and strength. Manhattan Scientifics has developed unique processing methodology for producing nanostructures in a wide range of ductile metals and alloys and is now commercializing this new and revolutionary technology.

Enhanced strength and fatigue resistance

Nanostructured metals and alloys offer many advantages for a wide range of structural applications. Application areas include biomedical structures, sports structures, aerospace and chemical structures, among others.

Technology : Nanomedecine


Manhattan Scientifics and Senior Scientific, LLC have announced that they have begun cooperative work to commercialize Senior Scientific's nano medicine cancer detection technology. Manhattan Scientifics acquired Senior Scientific, along with all its patents and IP in the emerging field of nano medicine; specifically Dr. Flynn's work in biomagnetic detection of cancer and other diseases through magnetic field sensors. These sensors make it possible to identify and image small clusters of cancer cells substantially increasing the sensitivity for finding cancer at an earlier stage than is currently available, and without the use of ionizing radiation or large magnetic fields. The biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate, melanoma, and other cancers. Dr. Flynn's research has been funded by the National Institute of Health (NIH). Management intends to identify one or more appropriate Fortune/500 industrial partners in the Big Pharma group to bring product to the market under royalty bearing licenses.

To learn more about Senior Scientific and the technologies being developed, please visit

About Nanomedicine

The term "Nanomedicine" is commonly used to describe the convergence of nanotechnology and pharmacology. It has been defined as "the science and technology of diagnosing, treating, and preventing disease and traumatic injury, or relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the human body" by the European Science Foundation. (European Science Foundation)

Nanomedicine will soon be used for diagnosing and treating cancer, musculoskeletal and inflammatory diseases, neurodegenerative diseases, diabetes and infectious diseases. In general, nanotechnology has the incredible potential to improve patient outcomes. What does this mean? Patients will be living longer with a greater quality of life!

In the fight against cancer, nanotechnology introduces unique approaches to diagnosis and treatment that could not even be imagined with conventional technology. New tools engineered at sizes much smaller than a human cell will enable researchers and clinicians to detect cancer earlier, treat it with much greater precision and fewer side effects, and possibly stop the disease long before it can do any damage.

Understanding Nanotechnology

Nanotechnology is the development and engineering of devices so small that they are measured on a molecular scale. This emerging field involves scientists from many different disciplines, including physicists, chemists, engineers, information technologists, and material scientists, as well as biologists. Nanotechnology is being applied to almost every field imaginable, including electronics, magnetics, optics, information technology, materials development and biomedicine.

The Size of Things

Nanoscale devices are one hundred to ten thousand times smaller than human cells. They are similar in size to large biological molecules ("biomolecules") such as enzymes and receptors. As an example, hemoglobin, the molecule that carries oxygen in red blood cells, is approximately 5 nanometers in diameter. Nanoscale devices smaller than 50 nanometers can easily enter most cells, while those smaller than 20 nanometers can move out of blood vessels as they circulate through the body.

Because of their small size, nanoscale devices can readily interact with biomolecules on both the surface and inside cells. By gaining access to so many areas of the body, they have the potential to detect disease and deliver treatment in ways unimagined before now.

Authorized Shares: 950 million -- As of March 3, 2014
There were 489,383,252 shares of common stock issued and outstanding as of March 21, 2014 (per 2013 10K).

Current SEC Filings: Click Here

All releases/news from official MHTX releases, unless noted

Pushing the Limits of Cancer Detection

(June 10, 2014) ALBUQUERQUE, N.M.-- Manhattan Scientifics, Inc. (OTCQB: MHTX) announced today that it has delivered its break-through, cancer measurement instrument to The University of Texas M.D. Anderson Cancer Center in Houston, TX. Full release

PrecisionMRX™ Nanoparticle Production Process Ready

(April 14, 2014) Building upon local relationships, Senior Scientific is stepping into the commercial space with first product introductions through Azano Biotech. Azano currently supplies research reagents to the same cancer researchers who will eventually be customers for the MRX II instrument. Full release

Progress on our First Major Product: the NanoMRXII

(March 19, 2014) The overarching mission for February has been to get the 9 Channel System up and running. We are delighted to be delivering this extraordinary device to our collaborators at MD Anderson. Full release

Manhattan Scientifics Announces Commercial Introduction Of NanoMRX Precision Nanoparticles

(March 18, 2014) ALBUQUERQUE, N.M. -- Manhattan Scientifics (OTCQB: MHTX) announced today a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase. Full release

MHTX Announces Collaboration with MD Anderson Cancer Center

(January 27, 2014) ALBUQUERQUE, N.M.--Manhattan Scientifics (OTC: MHTX) executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Dr. Flynn is the founder and chief scientist of MHTX’s subsidiary, Senior Scientific LLC. Senior Scientific is seeking to commercialize this patented non-invasive technology using ultra-sensitive magnetic detectors to locate, identify and measure tumors thousands of times smaller than detectable using current technologies. Full release

MHTX Announces Initiation of Coverage by Independent Equity Research Firm SeeThruEquity, LLC

(October 1, 2013) New York, NY – Manhattan Scientifics Inc. (OTCQB: MHTX) announced today that SeeThruEquity, LLC has initiated coverage on the Company. The report is now available for viewing at the following link.  Full release

MHTX Announces the Engagement of Loraine Upham to Market Its Cancer Diagnostic Technology

(August 23, 2013) Manhattan Scientifics announced today that Loraine Upham has been engaged as a consultant to support its cancer team. The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Full release

Senior Scientific Announces Issuance of U.S. Patent

(May 23, 2013) Senior Scientific, LLC, a unit of Manhattan Scientifics and a developer of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the United States Patent Office (USPTO) has issued U.S. Patent No. 8,447,379 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof." Full release

Manhattan Scientifics Announces Receipt of $2.5M Commitment to Build Breakthrough Cancer Detection

(April 9, 2013) NEW YORK--Manhattan Scientifics announced today that it has received the initial $1 million of a $2.5 million commitment to build the first generation of its advanced cancer detection devices. Full release

Interview with mobile phone inventor Marty Cooper

(April 3, 2013) The first mobile phone call was made 40 years ago today, on 3 April 1973. Martin Cooper, at the time a senior engineer at Motorola and now a member of our Science and Technology Committee, called a rival colleague at another telecoms company and announced he was speaking from "a 'real' cell telephone". Full release

Cancer Research: NFCR Cites MHTX’s Early Cancer Detection Tech as Research Breakthrough for 2012

(January 7, 2013) ALBUQUERQUE, N.M.--The National Foundation for Cancer Research (NFCR) has listed the SQUID-based cancer imaging technology developed by MHTX's (OTCBB: MHTX) Senior Scientific subsidiary as a "2012 Research Breakthrough." Full release


Film Highlighting Collaborative Work by CINT & Senior Scientific (June 13, 2014)

Senior Scientific Mag Needle - Explains the technology for identifying cancer.

Bloomberg Podcast of Interview with Dr. Flynn (January 12, 2011)

MHTX Press Conference Video (October 15, 2010)

KSFR nano technology interview - Audio (October 14, 2010)

Manhattan Scientifics & The LANL Pushing Frontiers (March 25, 2009)

Manhattan Scientifics Press Conference (July 2, 2008)

Manhattan Scientifics Press Conference (July 1, 2008)

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MHTX News: Quarterly Report (10-q) 11/13/2017 06:13:30 AM
MHTX News: Quarterly Report (10-q) 08/18/2017 02:41:37 PM
MHTX News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/15/2017 06:07:29 AM
MHTX News: Current Report Filing (8-k) 07/12/2017 05:01:54 PM
#6104   All the news that's fit to print VerminHex 12/12/17 10:00:16 AM
#6103 hunchboy 12/12/17 07:47:57 AM
#6102   I will listen to the CC tonight and hunchboy 12/11/17 09:12:35 AM
#6101   No Hillary. Complete totalitarianism. We will only answer hunchboy 12/07/17 11:22:35 AM
#6100   Notice how the questions must be emailed ahead ssc 12/06/17 02:54:32 PM
#6099   Ok Get your question ready. CC with prolux hunchboy 12/06/17 12:41:07 PM
#6098   It close the THE MARV version of Christmas hunchboy 12/05/17 01:17:22 PM
#6097   Tax loss selling season. When does it hunchboy 11/30/17 11:10:31 AM
#6096   Manny's friends put REAL money on the table hunchboy 11/30/17 11:06:54 AM
#6095   Manny has a BIG announcement on the metals hunchboy 11/30/17 10:57:15 AM
#6094   2000 S&P points 17,000 dow points and 4500 hunchboy 11/30/17 10:16:57 AM
#6093   Minus 36 percent in just three months with hunchboy 11/29/17 12:56:09 PM
#6092   If THE MARV lived in the House of hunchboy 11/27/17 01:00:09 PM
#6090   hunchboy, I would love to sell my 300 eatbytes 11/26/17 05:08:16 PM
#6089   Bytes please you need to stop think ing hunchboy 11/25/17 02:06:35 PM
#6088   You are correct. I stand corrected. eatbytes 11/25/17 01:42:27 PM
#6087   Not to cloud your dreams with reality, but ssc 11/25/17 11:33:33 AM
#6086   I may be way out in left field eatbytes 11/25/17 08:39:07 AM
#6085   Maybe that's what THE MARV is just a hunchboy 11/24/17 02:43:18 PM
#6084   Content bot. VerminHex 11/24/17 01:21:31 PM
#6083 Really hunchboy 11/24/17 10:56:15 AM
#6082   Good Luck Brian hunchboy 11/23/17 10:11:34 AM
#6081   IBX is down 40% off the IPO. VerminHex 11/20/17 08:10:21 PM
#6080   Then you need to sell right now.I think BRIAN111 11/20/17 12:20:56 PM
#6079   That leaves a person wondering why you believe VerminHex 11/20/17 12:07:07 PM
#6078   Its getting to crunch time for both these BRIAN111 11/18/17 07:48:48 PM
#6077   Want a good laugh? Check THE MARV's LinkedIn hunchboy 11/18/17 11:40:31 AM
#6076   Remember Patient capitol. How about Manny's bud who hunchboy 11/15/17 03:04:07 PM
#6075   I guess the metals business is really heating ssc 11/13/17 02:19:30 PM
#6074   Hell if I bought 22 million at 11 hunchboy 11/13/17 02:16:59 PM
#6073   What THE MARV did not say was He hunchboy 11/13/17 02:14:52 PM
#6072   THE MARV The Legend The Diluting hunchboy 11/13/17 02:11:58 PM
#6071   10-Q highlights: ssc 11/13/17 09:13:04 AM
#6070   IBX single digits on deck VerminHex 11/08/17 08:29:49 AM
#6069   That was not the comment of a patient VerminHex 11/07/17 10:39:16 PM
#6068   We just need to be a little more hunchboy 11/07/17 01:44:04 PM
#6067   The MARV has set up LLC,s all over hunchboy 11/03/17 02:08:19 PM
#6066   I believe Marv and the stooges have altered VerminHex 11/02/17 10:45:11 AM
#6065   Hex Please don't forget the Manny signed hunchboy 11/01/17 03:44:22 PM
#6064   Never saw that before. It's as if ssc 11/01/17 12:35:15 PM
#6063   Imagine the ribbing and good natured chuckling around VerminHex 11/01/17 12:26:59 PM
#6062   Seems like the only agreement Marv and Manny ssc 11/01/17 09:12:26 AM
#6061   If you breathe oxygen, Marv will sign an VerminHex 11/01/17 07:33:52 AM
#6060   I have owned this stock for ages and Gumby525 10/31/17 08:19:55 PM
#6059   US navy has a new class of equity hunchboy 10/27/17 07:34:49 AM
#6058   GREED IS the selfish lust for MORE power hunchboy 10/26/17 11:44:02 AM
#6057   Hype, dilute, eat lobster, hype dilute more eat hunchboy 10/26/17 11:17:04 AM
#6056   Understood. But how, better yet why, would ssc 10/26/17 09:13:02 AM
#6055   Like I said . trusting THE MARV is hunchboy 10/26/17 08:39:00 AM
#6053   Interesting. While safety and efficacy are important, ssc 10/25/17 11:47:35 AM